Skip to main content
. 2017 Aug 24;8(43):74791–74805. doi: 10.18632/oncotarget.20422

Figure 5. DATS treatment enhanced myocardial AMPK/ACC signaling and AKT/GSK-3β/HIF-1α signaling, which was inhibited by Compound C or LY294002.

Figure 5

(A). representative blots; (B). p-AMPK/AMPK ratio; (C). p-ACC/ACC ratio; (D). p-AKT/AKT ratio; (E). p-GSK3β/GSK3β ratio; (F). HIF-1α expression. Data are expressed as mean ± SEM, n = 6 in each group; **P < 0.01/*P < 0.05 vs the T1D+Sham group, ##P < 0.01/#P < 0.05 vs the T1D+MI/R+V group, $$P < 0.01/$P < 0.05 vs the T1D+MI/R+DATS group. T1D, type 1 diabetes; MI/R, myocardial ischemia-reperfusion; DATS, diallyl trisulfide; Com.C, Compound C; LY, LY294002.